{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Trend tests will be used to investigate the relationship between SBRT dose and response.","groups":[{"description":"Participants undergo Stereotactic Body Radiation Therapy in 5 fractions at least 40 hours apart over 10-18 days.\n\nThree dose levels: 40Gy and 45Gy all in 5 fractions. Each initial dose level will have 6 participants allocated to them. All participants are assessed at their 3 month post SBRT visit for Dose-Limiting Toxicities (DLTs). If ≤1 participant experiences a DLT, participants will be enrolled at the next dose level. If ≥3 participants experience a DLT, further accrual will be permanently halted and the study stopped. If 2 participants experience a DLT, then an additional 6 participants will be enrolled at the same dose level. In this setting, if ≤ 3/12 participants have a DLT, participants will be enrolled at the next dose level. If ≥ 4/12 participants have a DLT, further accrual will be permanently halted and the study stopped and 35 Gy will not be recommended as safe.\n\nThe dosing strategy for the 2nd (45Gy) cohort will be identical to the first.","id":"OG000","title":"Treatment (SBRT)"}],"populationDescription":"There was insufficient patient accrual to perform additional statistical analysis.","reportingStatus":"POSTED","timeFrame":"Up to 12 months","title":"Response Measured According to Standard Response Evaluation Criteria in Solid Tumors","type":"SECONDARY"}